Minoset | Market Exclusivity | US | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Minoset
US Exclusivities

PharmaCompass Sponsored Ads

Contact Supplier

Paracetamol

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Minoset

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

119 API Suppliers, 79 USDMF, 21 CEP/COS, 16 JDMF, 7 EU WC, 108 KDMF, 106 NDC API, 34 Listed Suppliers, $ API Reference Price

119 API Suppliers
79 USDMF
21 CEP/COS
16 JDMF
7 EU WC
108 KDMF
106 NDC API
34 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

42 Drugs in Development

42 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

2599 FDF Dossiers, 730 FDA Orange Book, 503 Europe, 291 Canada, 75 Australia, 375 South Africa, 625 Listed Dossiers

2599 FDF Dossiers
730 FDA Orange Book
503 Europe
291 Canada
75 Australia
375 South Africa
625 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SUPPOSITORY;RECTAL - 120MG, SUPPOSITORY;RECTAL - 325MG, SUPPOSITORY;RECTAL - 650MG, SUPPOSITORY;RECTAL - 80MG, CAPSULE;ORAL - 325MG;50MG;40MG;30MG, TABLET, EXTENDED RELEASE;ORAL - 325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 250MG;250MG;65MG, TABLET;ORAL - 325MG;37.5MG, SOLUTION;INTRAVENOUS - 1GM/100ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 300MG;15MG, TABLET;ORAL - 300MG;30MG, TABLET;ORAL - 300MG;60MG, TABLET;ORAL - 325MG;5MG, TABLET;ORAL - 325MG;50MG;40MG, TABLET;ORAL - 300MG;60MG

SUPPOSITORY;RECTAL - 120MG
SUPPOSITORY;RECTAL - 325MG
SUPPOSITORY;RECTAL - 650MG
SUPPOSITORY;RECTAL - 80MG
CAPSULE;ORAL - 325MG;50MG;40MG;30MG
TABLET, EXTENDED RELEASE;ORAL - 325MG;7.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 250MG;250MG;65MG
TABLET;ORAL - 325MG;37.5MG
SOLUTION;INTRAVENOUS - 1GM/100ML (10MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - 300MG;15MG
TABLET;ORAL - 300MG;30MG
TABLET;ORAL - 300MG;60MG
TABLET;ORAL - 325MG;5MG
TABLET;ORAL - 325MG;50MG;40MG
TABLET;ORAL - 300MG;60MG

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 2 Minakem, 1 Evonik, 14 Rochem International Inc, 32 SPI Pharma, 2 Seqens, 32 DKSH, 2 Pharm-RX Chemical, 11 Faran Shimi Pharmaceutical, 14 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 11 Gangwal Healthcare, 21 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Capital Farma, 1 Pramukh Pharmachem, 4 ACG Worldwide, 19 Actylis, 3 Aeon Procare, 4 Alcedo Pharmachem, 12 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 44 BASF, 8 Beneo, 2 Bioplus Life Sciences, 6 Clariant, 12 Corel Pharma Chem, 7 DFE Pharma, 4 Finar, 17 Gangwal Chemicals, 2 Huzhou Sunflower Pharmaceutical, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 5 Kima Chemical, 6 Lonza Capsugel, 27 Microlex e.U, 2 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 5 Novo Excipients, 5 Pharmatrans-Sanaq, 13 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 56 Roquette, 22 Seppic, 8 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 4 The Dow Chemical Company, 3 Ulanqab Kema New Material, 1 Valens Pharmachem, 5 Vasa Pharmachem, 3 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

142 Fillers, Diluents & Binders, 79 Thickeners and Stabilizers, 72 Solubilizers, 69 Coating Systems & Additives, 60 Taste Masking, 55 Topical, 51 Disintegrants & Superdisintegrants, 50 Direct Compression, 46 Parenteral, 40 Granulation, 40 Film Formers & Plasticizers, 39 Controlled & Modified Release, 39 Lubricants & Glidants, 28 Chewable & Orodispersible Aids, 26 Emulsifying Agents, 21 Co-Processed Excipients, 18 Rheology Modifiers, 15 Surfactant & Foaming Agents, 12 API Stability Enhancers, 9 Empty Capsules, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

142 Fillers, Diluents & Binders
79 Thickeners and Stabilizers
72 Solubilizers
69 Coating Systems & Additives
60 Taste Masking
55 Topical
51 Disintegrants & Superdisintegrants
50 Direct Compression
46 Parenteral
40 Granulation
40 Film Formers & Plasticizers
39 Controlled & Modified Release
39 Lubricants & Glidants
28 Chewable & Orodispersible Aids
26 Emulsifying Agents
21 Co-Processed Excipients
18 Rheology Modifiers
15 Surfactant & Foaming Agents
12 API Stability Enhancers
9 Empty Capsules
5 Coloring Agents
4 Vegetarian Capsules
1 Soft Gelatin

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 348 NEWS #PharmaBuzz

3 DATA COMPILATION #PharmaFlow
348 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions, 406 Finished Drug Prices, 20 Annual Reports

7 US Medicaid Prescriptions
406 Finished Drug Prices
20 Annual Reports

MARKET PLACE

179 APIs, 95 FDF Dossiers

179 APIs
95 FDF Dossiers

PATENTS & EXCLUSIVITIES

41 US Patents, 2 US Exclusivities, 3 Health Canada Patents

41 US Patents
2 US Exclusivities
3 Health Canada Patents

REF. STANDARDS & IMPURITIES

1 EDQM, 7 USP, 1 JP, 26 Others

1 EDQM
7 USP
1 JP
26 Others

ANALYTICAL

2 BioAnalytical Methods, 8 Analytical Methods

2 BioAnalytical Methods
8 Analytical Methods

$ API Ref.Price (USD/KG) : 7 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Name Reset all filters

2 All

01 1AFT PHARMS US

02 1GLENMARK PHARMS LTD

filter Product Reset all filters

2 All

01 2ACETAMINOPHEN; IBUPROFEN

filter Exclusivity Expiration Date Reset all filters

2 All

01 12024-11-03

02 12026-03-01

filter Exclusivity Code Reset all filters

2 All

01 1NP

02 1PC

Granules Paracetamol

Product Main Page

AFT PHARMS US

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Country

Virtual Booth

Digital Content

ACETAMINOPHEN; IBUPROFEN

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Exclusivity Code

NP

Exclusivity Expiration Date

2026-03-01

Application Number

209471

Product Number

1

Exclusivity Details

01

AFT PHARMS US

ACETAMINOPHEN; IBUPROFEN

Biotech Digital Meet

Not Confirmed

AFT PHARMS US

Country

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ACETAMINOPHEN; IBUPROFEN

Exclusivity Code : NP

Exclusivity Expiration Date : 2026-03-01

Application Number : 209471

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

GLENMARK PHARMS LTD

Contact Supplier

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

Digital Content

ACETAMINOPHEN; IBUPROFEN

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Exclusivity Code

PC

Exclusivity Expiration Date

2024-11-03

Application Number

218311

Product Number

1

Exclusivity Details

02

GLENMARK PHARMS LTD

ACETAMINOPHEN; IBUPROFEN

Biotech Digital Meet

Not Confirmed

GLENMARK PHARMS LTD

India

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

ACETAMINOPHEN; IBUPROFEN

Exclusivity Code : PC

Exclusivity Expiration Date : 2024-11-03

Application Number : 218311

Product Number : 1

Exclusivity Details :

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!